Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC

This is an observational study examining whether a measurement called residual volume tumor (RVT) — the amount of cancer remaining after targeted therapy before surgery — can predict long-term outcomes for people with non-small cell lung cancer (NSCLC) that has a specific gene mutation called EGFR. It aims to identify who responds best to pre-surgical drug treatment. **You may be eligible if...** - You are 18–80 years old - You have EGFR-mutated non-small cell lung cancer confirmed by pathology - You received neoadjuvant (pre-surgery) targeted therapy - You underwent definitive surgery for your lung cancer **You may NOT be eligible if...** - You have a history of prior chemotherapy, immunotherapy, or radiotherapy for this cancer - You have a history of another cancer or prior lung surgery - Key data needed for the study is missing from your records Talk to your doctor to see if this trial is right for you.